Blogs

Eroom’s Law highlights a troubling trend in pharmaceutical R&D: the cost and time required to develop new drugs have been steadily increasing despite technological advances (1). As a result, drug discovery is under constant pressure.

Global pharmaceutical supply chains are under sustained pressure from rising regulatory expectations, complex molecules, and frequent disruptions across geographies. For manufacturers handling highly potent active pharmaceutical ingredients (HPAPIs), the challenge is more pronounced.

Cell line development is a critical early step in biologics manufacturing. For monoclonal antibodies and other therapeutic proteins, the quality of the master cell bank determines not only expression levels but also long-term process stability, regulatory confidence, and downstream scalability.

Integrated cell line development and biologics development are reshaping veterinary therapeutics. Discover how multi-modality innovation drives impact—read more today.

Understand antibody drug conjugate science, bioconjugation, and manufacturing controls that shape targeted therapy for cancer. Read the article today.

Tech transfer sounds like a handover, but in a CDMO, it is a stress test. A process that behaves in a bench hood can shift when it meets plant-scale mixing, utilities, sampling routines, and tighter execution windows.

Self-amplifying RNA (saRNA) is emerging as the next wave in mRNA-based therapeutics, building on the achievements of first-generation mRNA vaccines and treatments.

Green chemistry principles have moved from being a “nice to have” idea to a practical framework that shapes how molecules are discovered, developed and manufactured.

See how chemistry, biology, DMPK, and DMTA expertise with a trusted preclinical CRO make integrated drug discovery faster and more reliable. Read now.

Clear guidance on bispecific antibodies, from formats and engineering to analytics and control strategy, for scalable development and manufacturing. Read now.